[go: up one dir, main page]

AR132294A1 - Inhibidores de kras - Google Patents

Inhibidores de kras

Info

Publication number
AR132294A1
AR132294A1 ARP240100806A ARP240100806A AR132294A1 AR 132294 A1 AR132294 A1 AR 132294A1 AR P240100806 A ARP240100806 A AR P240100806A AR P240100806 A ARP240100806 A AR P240100806A AR 132294 A1 AR132294 A1 AR 132294A1
Authority
AR
Argentina
Prior art keywords
kras inhibitors
pharmaceutically acceptable
acceptable salts
kras
inhibitors
Prior art date
Application number
ARP240100806A
Other languages
English (en)
Inventor
Adedoyin David Abraham
De La Cruz Alberto Valero
Andrew Dilger
Desta Bume
Soler Julin Priego
Vallejo Maria Lourdes Prieto
Mario Barberis
Sanz Miguel Garzn
Ramkumar Rajamani
Sean Aronow
Shane Michael Walls
Sanfeliciano Sonia Maria Gutierrez
Timothy Scott Kercher
Flrez Victoriano Molero
Xiaohong Chen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR132294A1 publication Critical patent/AR132294A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona compuestos de la fórmula: (1) en donde A, Z, G, R¹, R², y R⁴ son según se describe en la presente descripción, sales farmacéuticamente aceptables de estos y métodos para usar estos compuestos y sales farmacéuticamente aceptables de estos para tratar a pacientes con cáncer.
ARP240100806A 2023-03-30 2024-04-03 Inhibidores de kras AR132294A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363493051P 2023-03-30 2023-03-30
EP23382530 2023-06-02
EP23382855 2023-08-18

Publications (1)

Publication Number Publication Date
AR132294A1 true AR132294A1 (es) 2025-06-11

Family

ID=90789452

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240100806A AR132294A1 (es) 2023-03-30 2024-04-03 Inhibidores de kras

Country Status (8)

Country Link
US (1) US20240343736A1 (es)
KR (1) KR20250164300A (es)
CN (1) CN121079301A (es)
AR (1) AR132294A1 (es)
AU (1) AU2024245542A1 (es)
MX (1) MX2025011447A (es)
TW (1) TW202502320A (es)
WO (1) WO2024206747A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
TW202535880A (zh) * 2023-10-30 2025-09-16 大陸商江蘇恆瑞醫藥股份有限公司 稠合雜芳基類化合物、其製備方法及其在醫藥上的應用
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3325473A4 (en) 2015-07-22 2019-06-26 The Royal Institution for the Advancement of Learning / McGill University Compounds and uses thereof in the treatment of cancer and other medical disorders
IL274601B2 (en) 2017-11-15 2024-04-01 Mirati Therapeutics Inc Kras g12c inhibitors
AR116604A1 (es) 2018-10-15 2021-05-26 Lilly Co Eli Inhibidores de kras g12c
JP7592601B2 (ja) 2019-01-10 2024-12-02 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
PH12022550469A1 (en) 2019-08-29 2023-02-27 Array Biopharma Inc Kras g12d inhibitors
HUE060684T2 (hu) 2019-12-11 2023-04-28 Lilly Co Eli KRas G12C inhibitorok
US20240140957A1 (en) * 2021-01-08 2024-05-02 Beigene Switzerland Gmbh Bridged compounds as kras g12d inhibitor and degrader and the use thereof
IL304986A (en) * 2021-02-16 2023-10-01 Theras Inc Compositions and methods for inhibition of ras
EP4322954A4 (en) * 2021-04-16 2025-01-29 Merck Sharp & Dohme LLC SMALL MOLECULAR INHIBITORS OF THE KRAS G12D MUTANT
JP7668908B2 (ja) * 2021-06-09 2025-04-25 イーライ リリー アンド カンパニー Ｋｒａｓ ｇ１２ｄ阻害剤としての置換縮合アジン
CN119095853A (zh) * 2022-03-25 2024-12-06 伊莱利利公司 Kras抑制剂

Also Published As

Publication number Publication date
US20240343736A1 (en) 2024-10-17
WO2024206747A1 (en) 2024-10-03
KR20250164300A (ko) 2025-11-24
CN121079301A (zh) 2025-12-05
AU2024245542A1 (en) 2025-08-21
TW202502320A (zh) 2025-01-16
MX2025011447A (es) 2025-11-03

Similar Documents

Publication Publication Date Title
AR132295A1 (es) Inhibidores de kras
AR132294A1 (es) Inhibidores de kras
AR133985A1 (es) Inhibidores de kras
CL2024002874A1 (es) Inhibidores de kras
MX2025002170A (es) Inhibidores de kras g12c
AR116604A1 (es) Inhibidores de kras g12c
MX2024001824A (es) Compuestos heterociclicos y metodos de uso.
MX2024015363A (es) Compuestos de haloalquinilo para el tratamiento de cáncer
MX2022007969A (es) Inhibidores de egfr.
MX2023012726A (es) Compuestos heterociclicos y metodos de uso.
CY1124086T1 (el) Παραγωγα 3-τετραζολυλ-βενζεν-1,2-δισουλφοναμιδιου ως αναστολεις μεταλλο-βητα-λακταμασης
MX2025008591A (es) Inhibidores de cdk
CL2024000067A1 (es) Compuestos antivirales
ECSP20044709A (es) Inhibidores de sarcómero cardíaco
AR130425A1 (es) Inhibidores de kras(g12d)
CR20190124A (es) Inhibidores de ssao de aminopirimidina
MX2021011753A (es) Degradadores de moleculas peque?as de stat3.
MX2020007014A (es) Compuestos de benzamida.
MX2023004373A (es) Metodos y composiciones para la degradacion dirigida de proteinas.
CO2021017202A2 (es) Compuestos tricíclicos
CR20240203A (es) Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2
AR119557A1 (es) Compuestos de 7,8-dihidro-4h-pirazolo[4,3-c]azepina-6-ona
AR128894A1 (es) Inhibidores de kras
MX2024009441A (es) Compuestos de imidazopiridinilo sustituidos utiles como inhibidores del receptor tipo toll 9 (tlr9).
AR131945A1 (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno